Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Indomethacin (50 mg every eight hours) was given to 17 selected patients with pleurisy to control pain. Eleven of 17 obtained good to excellent relief of pain within 24 hours. Pain was not relieved in three patients and was only partly relieved in three others. Potentially serious side effects developed in two patients but resolved quickly. In selected patients indomethacin appears to be a reasonable initial choice for relief of pleural pain.
 ...
PMID:Effects of indomethacin on pleural pain. 620 94

161 patients with extra-articular or non-articular disorders as acute shoulder syndrome, periarthritis humero scapularis, syndrome of the angular of the scapula, acute olecranon bursitis, acute epicondylitis and/or epitrochleitis or periarthritis of the hip were treated in this double-blind multicenter study. 53 patients received 300 mg N-(2,6-dichloro-m-tolyl)anthranilic acid, sodium salt (meclofenamate sodium, Meclomen) per day for a maximum of 3 weeks, 54 received 150 mg indomethacin per day and 54 received placebo. Meclofenamate sodium was significantly superior to placebo in the treatment of such symptoms as spontaneous pain, pain on motion, tenderness on pressure associated with acute episodes of extra- or non-articular rheumatism as demonstrated by earlier and superior improvement. Indomethacin showed comparable efficacy. Adverse reactions, mostly gastrointestinal symptoms, were reported by 15 patients receiving meclofenamate sodium (28.3%), 26 patients taking indomethacin (48.2%) and 5 patients in the placebo group (9.3%). The tolerance of meclofenamate sodium was good with the distinct clinical impression that meclofenamate sodium was better tolerated than indomethacin.
 ...
PMID:Double-blind multicenter study comparing meclofenamate sodium with indomethacin and placebo in the treatment of extra-articular rheumatic disease. 634 50

In a prospective, randomized study, the prophylactic effect of indomethacin (150 mg daily) in regard to recurrence of ureteral colic was investigated in 78 patients. Severe recurrent attacks were experienced in 78 patients. Severe recurrent attacks were experienced by 4 of 37 patients in the test group and by 16 of the 41 controls without indomethacin. The mean duration of recurrent pain including the severe attacks was 5.6 +/- 1.1 hour/patient/week in the test group and 12.5 +/- 2.9 in the control group. Passage of stone within 7 days was not influenced by indomethacin (22/37 and 25/41 cases). Indomethacin administration for 7 days after an acute attack of ureteral colic thus reduced the frequency of severe attacks and the total duration of recurrent pain, without influencing the stone passage.
 ...
PMID:Indomethacin as prophylaxis against recurrent ureteral colic. 650 47

Indomethacin (100 mg. per day for 3 days) was tested for its prophylactic effects on the postsurgical complications of pain, swelling, and trismus after removal of impacted teeth. The drug resulted in a significant reduction of the swelling and an analgesic effect which was equal to that of acetaminophen and codeine. Only two minor side effects were encountered.
 ...
PMID:Prophylactic use of indomethacin for prevention of postsurgical complications after removal of impacted third molars. 657 32

Indomethacin is still used commonly for the treatment of rheumatic diseases but is associated with side effects, particularly headache, in a number of patients. A controlled or sustained release formulation of indomethacin might provide lower peak plasma levels and thus reduce side effects while still maintaining adequate plasma levels to control pain and inflammation. In this single dose crossover study, normal volunteers received the new formulation of indomethacin (Indocid GITS 6/85) fasting or with a standard meal, indomethacin 75 mg with a standard meal or indomethacin 25 mg three times daily with a standard meal. Plasma concentration data showed that peak plasma levels were reduced but the area under the plasma concentration curve was not significantly different between the four treatments.
 ...
PMID:Pharmacokinetics of an osmotically controlled delivery indomethacin preparation in normal volunteers. 662 54

In a prospective study, including fifty consecutive patients with acute ureteral-stone pain, the patients were randomly distributed into two groups for treatment. There were given either an intravenous injection of indomethacin (Confortid) 50 mg, or a subcutaneous injection of 2 mg hydromorphine chloride-atropine (Dilaudid-atropin 1 ml). Patients in the latter group also received a suppository of prochlorperazine (Stemetil) 25 mg. The analgesic effect of the two drugs did not differ significantly. Indomethacin was quicker acting, probably due to the intravenous route of administration. The side effects were alike but those caused by indomethacin had a tendency to be milder and of shorter duration.
 ...
PMID:A comparative study on the analgesic effects of indomethacin and hydromorphinechloride-atropine in acute, ureteral-stone pain. 663 13

Studies on the therapeutic effect of nonsteroidal anti-inflammatory agents in relation to doses or plasma concentrations have been relatively rare. We have investigated the clinical effects of indomethacin in daily doses of 45, 75 and 105 mg compared with placebo. The treatments were given double blind in two-week periods to eight rheumatic patients. There was a statistically significant therapeutic effect on parameters related to pain but no effect was detected on the activity of the disease by technetium scintigraphy. There was no clear association between dose or plasma concentration of indomethacin and therapeutic response in the actual patients with the dose range used. In a subsequent study ASA was given double blind in daily doses of 2 and 4.5 g in two three-week periods to twelve rheumatic patients. Placebo and indomethacin were given as suppositories at night and the clinical effect was evaluated by articular index and subjects rating of morning stiffness and pain. Prostaglandin release from platelets was assessed by a RIA method. It was found that both doses of ASA suppressed the PGF2alpha release totally. Indomethacin had a significant additive effect during 2 g ASA therapy as estimated by articular index and subjective ratings of pain and morning stiffness. On the 4.5 g ASA dose there was a significant improvement only for articular index. Thus the release of PGF2alpha cannot be used as a measure of antirheumatic effect and the clinical practice to combine these drugs seems justified. As the dose of ASA was increased from 2 to 4.5 g daily the total salicylate concentration increased up to 5 times. The unbound and pharmacologically active concentration increased up to 24 times. This disproportionality reflects the combined effect of capacity limited metabolism and capacity limited protein binding of salicylate.
 ...
PMID:Clinical effects of indomethacin and additive clinical effect of indomethacin during salicylate maintenance therapy. 694 53

Indomethacin 0, 15, 25 and 35 mg t.i.d. was given in randomized order for two weeks to eight outpatients with rheumatoid arthritis in a double-blind study. At the end of each treatment period the clinical response was evaluated by subjective and objective methods and the plasma indomethacin concentration was measured by GLC-mass fragmentography. Compared with non-treatment periods, indomethacin had a statistically significant therapeutic effect as judged by global assessment, duration of morning stiffness, use of escape analgesia, articular index and pain score, but there was no relation between the clinical effect and the size of the dose or the plasma concentration of the drug. Technetium uptake over the affected joints did not change during indomethacin therapy, which might reflect a lack of effect on the local activity of the disease. Lower doses than those currently prescribed are probably sufficient to alleviate symptoms in this disease.
 ...
PMID:Double-blind dose-response study of indomethacin in rheumatoid arthritis. 699 34

Twelve rheumatic patients were given 2.0 and 4.5 g acetylsalicylic acid daily in two 3-week periods. On days 13 and 20 of each period the patients took a suppository containing either placebo or 50 mg of indomethacin. The study was performed double-blind. Indomethacin had a significant additive effect during ASA therapy with 2 g daily as estimated by articular index and subjective ratings of pain and morning stiffness. On the 4.5 g ASA dose there was a significant improvement only for articular index. The patients experienced less pain during maintenance therapy with 4.5 g of ASA compared with 2.0 g daily. Both ASA doses induced complete inhibition of prostaglandin PGF2 alpha release from platelets. Thus the suppression of PGF2 alpha release does not reflect the therapeutic response of these drugs. Side effects observed comprised tinnitus, dizziness and gastritis. In 2 of the patients the aminotransferase levels increased, indicating hepatotoxicity. The protein binding of salicylate decreased with increasing salicylate concentration. As the dose was increased from 2.0 to 4.5 g/day the unbound concentration increased 5 to 24 times. This reflects the combined effect of capacity-limited metabolism and capacity-limited protein binding of salicylate.
 ...
PMID:Additive clinical effect of indomethacin suppositories during salicylate therapy in rheumatoid patients. 701 17

Using microtransducer, the author has studied the uterine contraction in various menstrual phases and during dysmenorrhea, and also the effect of the administration of PG synthetase inhibitors. The results obtained can be summarized as follows: 1) In normal non-gravid uterus, the contraction was 25.6mmHg in amplitude and 19.9/10min. in frequency in the proliferative phase, 12.4 and 28.4 in the early half of secretory phase, 28.3 and 11.5 in the latter half, and 42.3 and 12.9 during menstruation. In other words, while the contractions were the most pronounced during menstruation, no difference was found between proliferative and the latter half of secretory phase, and they were the weakest during the early half of secretory phase with the ripple like small waves. 2) During the proliferative phase, relatively regular contractions were found in various kinds of patients, - that is - , patients with normal menstrual cycles, with organic disorders but without dysmenorrhea, with functional dysmenorrhea, or with organic dysmenorrhea. 3) Compared to other menstrual phases, the contractions were weak in the early half of secretory phase. However, the patients with organic dysmenorrhea had stronger contractions than other patients. 4) In the latter half of secretory phase, the patients with organic disorders or organic dysmenorrhea showed stronger contractions than in those without the organic changes, and the contractions were approximately 55mmHg in amplitude in patients with organic change, -almost twice higher than in patients without organic change. 5) During menstruation, patients with dysmenorrhea, functional or organic, showed contractions with the average amplitude of 87mmHg, -more than twice the height found in the patients without dysmenorrhea. 6) When the amplitude was higher then 140mmHg, all the patients complained of pain. 7) In patients with dysmenorrhea, the administration of PG synthetase inhibitors, such as Indomethacin, Naproxen, etc., caused the reduction of contraction amplitude, resulting in the relief of pain.
 ...
PMID:[Contraction of non-gravid human uterus in various menstrual phases (author's transl)]. 706 50


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>